Next year will be a “landmark” one for GlaxoSmithKline, according to CEO Emma Walmsley — though many of the biggest changes she forecasted may not become evident until next year.
On next year’s agenda: fresh data from clinical trials of a vaccine for respiratory syncytial virus, a very common childhood illness; a Food and Drug Administration decision for daprodustat, GSK’s experimental treatment for a type of anemia; and the de-merger of GSK’s consumer business from its pharmaceutical arm — twenty-one years after the massive merger that created GlaxoSmithKline in the first place.
Demonstrating some immediate change is also particularly important to GSK, as it is currently the target of some activist investor firms. Among those is Elliott Management Corporation, a notorious hedge fund that has bought up significant stakes in the UK-based company.
About the Author Reprints
